BI and Lilly's Jardiance reverses heart failure in animal models by Arlene Weintraub Friday, April 19, 2019 Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.
Lilly, Pfizer's pain data show mixed efficacy, safety issues by Nick Paul Taylor Friday, April 19, 2019 Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.
Artios nabs Eli Lilly, AZ R&D veteran by Ben Adams Monday, April 1, 2019 Artios Pharma is the latest biotech to call a pharma executive into the startup fold as it poaches Ian Smith, M.D., as its new chief medical officer.
ACC: Merck anacetrapib reveal bodes neutral at best for DalCor by Amirah Al Idrus Wednesday, March 20, 2019 At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis
As Merck boosts R&D pact, NGM Bio gains new R&D chief by Ben Adams Wednesday, March 20, 2019 It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.
After a hiring blitz, Karuna nabs $68M funding round by Ben Adams Monday, March 18, 2019 Boston startup Karuna Therapeutics has raised a chunky $68 million as it looks to beef up work on its Alzheimer’s/schizophrenia combo therapy.
Karuna hires ex-Lilly scientist for CNS drug quest by Nick Paul Taylor Wednesday, March 13, 2019 The appointment reunites Christian Felder with xanomeline, a once-failed Alzheimer’s disease drug he helped through early development at Eli Lilly.
Pfizer licenses AnTolRx's immune tolerance medicine for diabetes by Amirah Al Idrus Tuesday, March 5, 2019 Two years after leading AnTolRx's $4 million series A, Pfizer is moving on an option to take over development of the upstart's lead candidate.
Pfizer, Lilly’s NGF painkiller meets endpoints in low back pain by Conor Hale Tuesday, February 19, 2019 Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.
Lilly cuts a trio of pipeline assets, including BTK inhibitor by Amirah Al Idrus Wednesday, February 6, 2019 The Big Pharma has culled a dual amylin calcitonin receptor agonist, a BTK inhibitor and a urocortin-2 peptide.
